A retrospective study of 30 cases evaluating the efficacy and safety of anlotinib plus Temozolomide for recurrent/residual glioma from a single center. Xu L, Yu D, Li F, Ding X, et al. BMC Cancer 2025;25:1623.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Xu L, Yu D, Li F, Ding X, et al. A retrospective study of 30 cases evaluating the efficacy and safety of anlotinib plus Temozolomide for recurrent/residual glioma from a single center. BMC Cancer 2025;25:1623.
PMID: 41126110